Advertisement

Pharmakotherapie neuropsychiatrischer Notfall- und Akutsituationen

  • H. Berzewski
  • G. Laux
  • L. Frölich
  • J. Fritze
  • H. Przuntek

Zusammenfassung

Die Häufigkeit psychiatrischer Notfälle hat im Verlauf der letzten zwei Jahrzehnte kontinuierlich zugenommen. Einen Einfluß hierauf haben die zunehmende Spezialisierung der medizinischen Fachgebiete und die Verkürzung und Intensivierung klinischer Behandlungsformen. Bedingt durch die starke Reduktion psychiatrischer Betten und die Regionalisierung der psychiatrischen Versorgung mit der Folge, daß in größerer Zahl psychiatrische Abteilungen in Allgemein-Krankenhäusern angesiedelt sind, werden in den Erste-HilfeStationen und Ambulanzen der Allgemein-Krankenhäuser vermehrt Patienten mit akuten psychischen Störungen eingeliefert. Ein weiteres Problem ist darin zu sehen, daß der Psychiater nur in Ausnahmefällen der erstuntersuchende Arzt bei psychiatrischen Notfällen ist: In der Regel wird an erster Stelle der diensthabende Arzt im Krankenhaus oder der in der Praxis niedergelassene fachfremde Kollege mit dem Notfall konfrontiert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baehr R (1988) Psychiatrisches Notfallrecht. Nervenheilkunde 7: 323–328Google Scholar
  2. Bassuk EL, Skodol AE (1984) The first few minute. In: Bassuk EL, Birk AW (eds) Emergency psychiatry. Concepts, methods and practices. Plenum Press, New York London, pp 21–33Google Scholar
  3. Bassuk EL, Winter R, Apsler R (1983) Cross cultural comparison of British and American psychiatric emergencies. Am J Psychiatry 140: 180–184PubMedGoogle Scholar
  4. Bristol HJ, Giller E, Docherty JP (1981) Trends in emergency psychiatry in the last two decades. Am J Psychiatry 138: 623–628PubMedGoogle Scholar
  5. Evenson R, Waite J, Holland R (1983) Admission decisions in the psychiatric emergeency room. Compr Psychiatry 24: 90–93PubMedGoogle Scholar
  6. Friedman Cth, Lesser IM, Auerbach E (1982) Psychiatric urgency as assessed by patients and their therapists at an adult outpatient clinic. Hosp Commun Psychiatry 33: 663–664Google Scholar
  7. Gerson S, Bassuk E (1980) Psychiatric emergencies: an overview. Am J Psychiatry 137: 1–11PubMedGoogle Scholar
  8. Häfner H, Helmchen H (1978) Psychiatrischer Notfall und psychiatrische Krise — Konzeptuelle Fragen. Nervenarzt 49: 82–87PubMedGoogle Scholar
  9. Häfner-Ranabauer W, Günzler G (1984) Entwicklung und Funktion des psychiatrischen Krisen-und Notfalldienstes in Mannheim. Fortschr Neurol Psychiat 52: 83–90PubMedGoogle Scholar
  10. Hillard FR, O“Shanik GJ, Houpt JL (1982) Residency training in the psychiatric emergency room. Am J Psychiatry 139: 236–238Google Scholar
  11. Kaskey GB, Janzito BM (1984) Development of an emergency psychiatric treatment unit. Hosp Commun Psychiatry 35: 1220–1222Google Scholar
  12. Katschnig H (1980) Sozialer Streß und psychische Erkrankung. Urban & Schwarzenberg, MünchenGoogle Scholar
  13. Katschnig H, Konieczna T (1986) Notfallpsychiatrie und Krisenintervention. In: Kisker KP, Lau-Ter H, Meyer JE, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart, Bd 2. Krisenintervention-Suizid-Konsiliarpsychiatrie. Springer, Berlin Heidelberg New York Tokyo, S 3–43Google Scholar
  14. Kreitman N (1977) Parasuicide. John Wiley & Sons, LondonGoogle Scholar
  15. Madden DJ, Lion JR, Penna NW (1976) Assaults on psychiatrists by patients. Am J Psychiatry 133: 422–425PubMedGoogle Scholar
  16. Mcniel DE, Binder RL (1987) Patients who bring weapons to the psychiatric emergency room. J Clin Psychiatry 48: 230–233Google Scholar
  17. Robins E, Gentry KA, Munoz RA, Marten S (1977) A contrast of the three more common illnesses with the ten less common in a study and 18-month follow-up of 3/4 psychiatric emergency room patients I and II. Arch Gen Psychiatry 34: 259–265, 269–281Google Scholar
  18. Rusk TN, Gerner RH (1972) A study of the process of emergency psychotherapy. Am J Psychiatry 128: 882–887PubMedGoogle Scholar
  19. Shephard M, Davies B, Cuepan RH (1960) Psychiatric illness in the general hospital. Acta Psychiatr Neurol Scand 35: 518–525Google Scholar
  20. Summers WK, Douglas A, Rund MD, Lewin M (1979) Psychiatric illness in a general urban emergency room: daytime versus nighttime population. J Clin Psychiatry 40: 340–343PubMedGoogle Scholar
  21. Talbott JA (1981) The chronic mentally ill. In: Arieti S, Brodic Hkh (eds) American handbook of psychiatry, 2nd ed, vol 7. Advances and new directions. Basic Books, New York, pp 369–387Google Scholar
  22. Walker JI (1983) Psychiatric emergencies. Intervention resolution. Lippincott, Philadelphia London Mexico City New York St. Louis Sao Paulo SydneyGoogle Scholar
  23. Achte K (1975) Suizidalität und Suizidverhütung. Munch Med Wochenschr 117: 189–192Google Scholar
  24. Arora RC, Meltzer HY (1989) Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 146: 730–736PubMedGoogle Scholar
  25. Asberg M, Nordstrom P (1988) Biological correlates of suicidal behavior. In: Möller HJ et al.(eds) Current issues of suicidology. Springer, Berlin Heidelberg New York Tokyo, pp 223–241Google Scholar
  26. Asberg M, Schalling D, Träskman-Bendz L, Wagner A (1987) Psychobiology of suicide, impulsivity, and related phenomena. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 655–669Google Scholar
  27. Avery D, Winokur G (1978) Suicide, attempted suicide, and relapse rates in depression. Arch Gen Psychiatry 35: 749–753PubMedGoogle Scholar
  28. Barraclough B, Bunch J, Nelson B, Sainsbury P (1974) A hundred cases of suicide: clinical aspects. Br J Psychiatry 125: 355–373PubMedGoogle Scholar
  29. Beasley CM, Dornseif BE, Bosomworth JC et al. (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 303: 685–692Google Scholar
  30. Breier A, Astrachan BM (1984) Characterization of schizophrenic patients who commit suicide. Am J Psychiatry 141: 206–209PubMedGoogle Scholar
  31. Burk F, Kurz A, Müller HJ (1985) Suicide risk scales: do they help to predict suicidal behaviour? Eur Arch Psychiatr Neurol Sci 235: 153–157Google Scholar
  32. Causeman B, Müller-Oerlinghausen (1988) Does lithium prevent suicides and suicidal attempts? In: Birch NJ (ed) Lithium inorganic pharmacology and psychiatric use. IRL, OxfordGoogle Scholar
  33. Farmer RDT, Pinder RM (1989) Why do fatal overdose rates vary between antidepressants? Acta Psychiatr Scand 80 [Suppl 3541: 25–35Google Scholar
  34. Häfner H, Helmchen H (1978) Psychiatrischer Notfall und psychiatrische Krise — Konzeptuelle Fragen. Nervenarzt 49: 82–87PubMedGoogle Scholar
  35. Haenel T (1989) Suizidhandlungen. Neue Aspekte der Suizidologie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  36. Hall RCW, Zisook S (1981) Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 11: S99–104Google Scholar
  37. Hleeard JR (1983) Emergency management of the suicidal patient. In: Walker JI (ed) Psychiatric emergencies. Lippincott, Philadelphia, pp 101–123Google Scholar
  38. Hyman SE (1988) Der suizidale Patient. In: Hyman SE (Hrsg) Psychiatrische Notfälle. Enke, Stuttgart, S 15–22Google Scholar
  39. Inman Whw (1988) Blood disorders and suicide in patients taking mianserin or amitriptyline. Lancet i: 90–92Google Scholar
  40. Laux G, König W (1992) Infusionstherapie bei Depressionen, 3. Aufl. Hippokrates, StuttgartGoogle Scholar
  41. Leonard BE (1989) Suicide prevention and anti- depressants. Acta Psychiatr Scand 80 [Suppl] 35–41Google Scholar
  42. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ (1989) Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry 155 [Suppl] 81: 7–14Google Scholar
  43. Miles CP (1977) Conditions predisposing to suici- de: a review. J Nerv Ment Dis 164: 231–246PubMedGoogle Scholar
  44. Modestin J (1985) Antidepressive therapy in depressed clinical suicides. Acta Psychiatr Scand 71: 111–116PubMedGoogle Scholar
  45. Müller HJ, Lauter H (1985) Der psychiatrische Liaisondienst. Munch Med Wochenschr 127: 842–845Google Scholar
  46. Montgomery SA, Montgomery D (1982) Pharmacological prevention of suicidal behaviour. J Affective Disord 4: 291–298Google Scholar
  47. Montgomery SA, Pinder RM (1987) Do some antidepressants promote suicide? Psychopharmacology 92: 265–266PubMedGoogle Scholar
  48. Muijen M, Roy D, Silverstone T, Mehmet A, Christie M (1988) A comparative clinical trial of fluoxe- tine, mianserin and placebo with depressed outpatients. Acta Psychiatr Scand 78: 384–390PubMedGoogle Scholar
  49. Pohlmeier H (1987) Suizidalität: Erkennung und Behandlung. Fortschr Pharmakother 3: 51–62Google Scholar
  50. Poldinger W (1982) Erkennung und Beurteilung der Suizidalität. In: Reimer C (Hrsg) Suizid. Springer, Berlin Heidelberg New York, S 13–21Google Scholar
  51. Poldinger W, Sonneck G (1980) Die Abschätzung der Suizidalität. Nervenarzt 51: 147–151PubMedGoogle Scholar
  52. Pokorny AD (1983) Prediction of suicide in psychiatric patients. Arch Gen Psychiatry 40: 249–257PubMedGoogle Scholar
  53. Reimer C (1982) (Hrsg) Suizid. Springer, Berlin Heidelberg New YorkGoogle Scholar
  54. Roy A (1982a) Risk factors for suicide in psychia-tric patients. Arch Gen Psychiatry 39: 1089–1095PubMedGoogle Scholar
  55. Roy A (1982b) Suicide in chronic schizophrenia. Br J Psychiatry 141: 171–177PubMedGoogle Scholar
  56. Rush AJ, Beck AT (1978) Cognitive therapy of depression and suicide. Am J Psychother 32: 201–219PubMedGoogle Scholar
  57. Schmidtke A (1992) Werden Suizidhandlungen in der Bevölkerung seltener? Neue epidemiologische Ergebnisse. Nervenheilkunde 11: 32–35Google Scholar
  58. Schmidtke A, Schaller S (1981) Möglichkeiten und Grenzen testpsychologischer Diagnostik suizidalen Verhaltens. In: Welz R et al. (Hrsg) Selbstmordhandlungen. Beltz, Weinheim, S 222–295Google Scholar
  59. Schmidtke A, Hafner H (1985) Suizide und Suizid-versuche. Minch Med Wochenschr 127: 828832Google Scholar
  60. Schou M, Weeke A (1988) Did manic-depressive patients who committed suicide receive prophylactic or continuation treatment at the time? Br J Psychiatry 153: 324–327PubMedGoogle Scholar
  61. Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147: 207–210PubMedGoogle Scholar
  62. Wakelin JS (1988) The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? Adv Biol Psychiatry 17: 70–83Google Scholar
  63. Welz R (1983) Drogen, Alkohol und Suizid. Enke, StuttgartGoogle Scholar
  64. Wilkinson G, Bacon NA (1984) A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychol Med 14: 899–912PubMedGoogle Scholar
  65. Wolfersdorf M (1992) Stellung von Psychopharmaka in der Behandlung von Suizidalität. Psychiat Prax 19: 100–107Google Scholar
  66. Agricola R, Mazzarino M, Vrani R, Vallo V, Grossi E (1982) Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride. J Int Med Res 10: 160–165PubMedGoogle Scholar
  67. Athen D (1986) Vergleichende Untersuchung von Clomethiazol und Neuroleptika bei der Behandlung des Alkoholdelirs. In: Evans JG, Feu-Erlein W, Glatt MM, Kanowski S, Scott OB (Hrsg) Clomethiazol. Verlag für Angewandte Wissenschaften, München, S 137–140Google Scholar
  68. Athen D, Hippius H, Meyendorf R, Riemer C, Steiner C (1977) Ein Vergleich der Wirksamkeit von Neuroleptika und Chlomethiazol bei der Behandlung des Alkoholdelirs. Nervenarzt 48: 528–532PubMedGoogle Scholar
  69. Bischoff HL (1969) Zur Pathogenese des Alkoholdelirs. Nervenarzt 40: 318–325Google Scholar
  70. Björquist SE, Isohami M, Mäkelà R, Malinen L (1976) Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand 53: 333–342Google Scholar
  71. Bruhne F (1966) Anhebung der Krampfschwelle als therapeutisches Prinzip bei der Behandlung von Alkoholdelirien. Nervenarzt 37: 415–418Google Scholar
  72. Cote WR, Lisnow FD (1984) Alcohol use and abuse. In: Bassuk EL, Birk AW (eds) Emergency psychiatry. Concepts, methods, and practices. Plenum Press, New York London, pp 129–139Google Scholar
  73. Daunderer M (1983) Physostigmin als Delir-Prophylaktikum beim ambulanten Alkohol-Entzug. Fortschr Med 101: 777–778Google Scholar
  74. Dencker SJ, Wilhelmson G, Carlsson E, Berben FJ (1978) Piracetam and chlormethiazole in acute alcohol withdrawal: a controlled clinical trial. J Int Med Res 6: 395–400PubMedGoogle Scholar
  75. Dworacek B, Rating W Ruprecht J, Lommers C (1982) Die Therapie des zentralen anticholinergen Syndroms. In: STÖCKEL H (Hrsg) Das zentralanticholinerge Syndrom: Physostigmin in der Anaesthesie und Intensivmedizin. Thieme, Stuttgart New York, S 42–51Google Scholar
  76. Feuerlein W (1967) Klinisch-statistische Untersuchungen über die Entstehungsbedingungen und die Prognose des Alkoholdelirs. Nervenarzt 38: 492–500PubMedGoogle Scholar
  77. Feuerlein W, Reiser E (1986) Parameters affecting the course and results of delirium tremens treatment. Acta Psychiatr Scand 73 [Suppl 3291: 120–123Google Scholar
  78. Flygenring J, Hansen J, Holst B, Peterson E, Soren Sen A (1984) Treatment in alcohol withdrawal symptoms in hospitalized patients. A rando- mized, double-blind comparison of carbama- zepine (Tegrol) and barbital ( Diemal ). Acta Psychiatr Scand 69: 398–408Google Scholar
  79. Giacobini E, Salum I (1961) Treatment of delirium tremens. Acta Psychiatr Scand 37: 198–208PubMedGoogle Scholar
  80. Glatt MM (1978) Chlomethiazol addiction. Br Med J: 894–895Google Scholar
  81. Granacher RP, Baldessarini RJ (1975) Physostigmin. Its use in acute anticholinergic syndromes with antidepressant and antiparkinson drugs. Arch Gen Psychiatry 32: 375–380Google Scholar
  82. Greenblatt DJ, Shader RI (1975) Treatment of the alcohol withdrawal syndrome. In: Shader RI (ed) Manual of psychiatric therapeutics: practical psychiatry and psychopharmacology. Little, Brown & Co, Boston, pp 211–235Google Scholar
  83. Holzbach E, Bühler KE (1978) Die Behandlung des Delirium tremens mit Haldol. Nervenarzt 49: 405–409PubMedGoogle Scholar
  84. Huffmann G, Becker T (1986) Behandlung des Delirium tremens und unvollständiger Alkoholdelirien — ein historischer Rückblick. In:Google Scholar
  85. Evans JG, Feuerlein W, Glatt MM, Kanowski S, Scorr OB (Hrsg) Clomethiazol. Verlag für Angewandte Wissenschaften, München, S 110–113Google Scholar
  86. Kanzow WT (1986) Klinische Stadien des alkoholischen Delirs und ihre therapeutische Bedeutung. In: Evans JG, Feuerlein W, Glatt MM, Kanowski S, Scurr OB (Hrsg) Clomethiazol. Verlag für Angewandte Wissenschaften, München, S 98–102Google Scholar
  87. Ladewig D, Levin P, Gastpar M, Gerthing P, Roth E (1978) Der Einsatz von Betablockern in der Behandlung des Abstinenzsyndroms. In: Kielholz P (Hrsg) Betablocker und Zentralnervensystem. Huber, Bern Stuttgart Wien, S 154–162Google Scholar
  88. Lauter H (1988) Die organischen Psychosyndrome. In: Kisker KP, Lauter H, Meyer JE, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart, Bd 6. Organische Psychosen. Springer, Berlin Heidelberg New York Tokyo, S 3–56Google Scholar
  89. Lauvén PM (1985) Das klinische Bild des zentralanticholinergen Syndroms. In: Stoeckel H, Lau-Yen PH (Hrsg) Monographie zum II. Symposium über “Das zentrale anticholinerge Syndrom: Physostigmin in der Psychiatrie-Intensivmedizin-Anaesthesiologie”, 9. März 1985, Bonn. Thieme, StuttgartGoogle Scholar
  90. Link J, Schulz H, Dennhardt R (1985) Häufigkeit des ZAS in der Anaesthesie unter besonderer Berücksichtigung der Narkosen mit volatilen Anaesthetika. In: Stoeckel H, Lauvén PH (Hrsg) Monographie zum II. Symposium über “Das zentrale anticholinerge Syndrom: Physostigmin in der Psychiatrie-Intensivmedizin-Anaesthesiologie”, 9. März 1985, Bonn. Thieme, StuttgartGoogle Scholar
  91. Madden JS, Jones D, Frisch EP (1969) Chlomethiazole and trifluoperazine in alcohol withdrawal. Br J Psychiatry 115: 1191–1192PubMedGoogle Scholar
  92. Marks NS (1977) Controlled clinical trial of piracetam in the treatment of the alcoholic withdrawal phase. Acta Ther 3: 181–190Google Scholar
  93. Mcgrath SD (1957) A controlled trial of chlomethiazole and chlordiazepoxyd in the treatment of the acute withdrawal phase of alcoholism. Br J Addict 70: 81–90Google Scholar
  94. Murphy DJ, Shaw GK, Clarke J (1983) Tiapride and chlormethiazole in alcohol withdrawal: a double blind trial. Alcohol Alcohol 18: 227–237Google Scholar
  95. Palson A (1986) Die Wirksamkeit frühzeitiger Clomethiazol-Medikation zur Prävention des Delirium tremens. Eine retrospektive Studie über das Ergebnis verschiedener medikamentöser Behandlungsstrategien in den Psychiatrischen Kliniken, Helsingborgs, 1975–1980. In: Evans JO, Feuerlein W, Glatt MM, Kanowski S, Scott OB (Hrsg) Clomethiazol. Verlag für Angewandte Wissenschaften, München, S 114–119Google Scholar
  96. Riotola E, Malinen L (1981) A double blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal symptoms. Acta Psychiatr Scand 64: 254–259Google Scholar
  97. Schied HW, Braunschweiger M, Schuppmann A (1986a) Die Behandlung des Delirium tre- mens in den Psychiatrischen Krankenhäu- sern der Bundesrepublik Deutschland. In:Google Scholar
  98. Evans JG, Feuerlein W, Glatt MM, Kanowski S, Scott OB (Hrsg) Clomethiazol. Verlag für Angewandte Wissenschaften, München, S 121–125Google Scholar
  99. Schied HW, Braunschweiger M, Schuppmann A (1986b) Das Delirium tremens vor und nach der Einführung und Verfügbarkeit des Clome- thiazol — ein historischer Vergleich anhand von 362 Fällen. In: Evans JG, Feuerlein W, Glatt MM, Kanowski S, Scarf OB (Hrsg) Clomethiazol. Verlag für Angewandte Wissenschaften, München, S 126–131Google Scholar
  100. Sutton T (1813) Tracts on delirium tremens, on peritonitis, on some other internal inflamminatory affections, and on gout. T Underwood, LondonGoogle Scholar
  101. Ulbricht B (1976) Über die klinische Anwendung von Piracetam bei chronischem Alkoholismus und dessen Komplikationen. Prädelir und Delir. Med Welt 27: 1912–1915PubMedGoogle Scholar
  102. Walther JI (1983) Psychiatric emergencies. Intervention and resolution. Lippincott, Philadelphia London Mexico City New York St. Louis Sao Paulo SydneyGoogle Scholar
  103. Wilkins AJ, Imkins WJ, Steiner JA (1983) Efficacy of clonidine in treatment of alcohol withdrawal state. Psychopharmacology 81: 78–80PubMedGoogle Scholar
  104. Anderson WH, Huehnle JC, Catanzano DM (1976) Rapid treatment of acute psychosis. Am J Psychiatry 133: 1076–1078PubMedGoogle Scholar
  105. Ayd Frjr (1980) Guidelines for using intramuscular Haloperidol for rapid neuroleptisation. In: Ayd FR JR (ed) Haloperidol update neuroleptisation. Ayd Medical Communications, Baltimore, pp 53–65Google Scholar
  106. Bassuk EL, Schoonover SC, Gelenberg EJ (eds) (1983) The practitioner’s guide to psychoactive drugs, 2nd ed. Plenum, New YorkGoogle Scholar
  107. Brodsky L, Pieszynski B (1985) The use of antidepressants in a psychiatric emergency department. J Clin Psychopharmacol 5: 35–38PubMedGoogle Scholar
  108. Carter RG (1977) Psychotolysis with haloperidol: rapid control of the acutely disturbed psychotic patient. Dis New Syst 38: 237–239Google Scholar
  109. Donlon PT, Tupin JP (1974) Rapid “digitalisation” of decompensated schizophrenic patients. Am J Psychiatry 131: 310–312PubMedGoogle Scholar
  110. Donlon PT, Hopkin J, Tupin JP (1979) Overview: efficacy and safety of the rapid neuroleptisation method with injectable haloperidol. Am J Psychiatry 136: 273–278PubMedGoogle Scholar
  111. Donlon PT, Hopkin JT, Tupin JP, Wicks JJ, Wabba M, Meadow A (1980) Haloperidol for acute schizophrenic patients. Arch Gen Psychiatry 37: 691–695PubMedGoogle Scholar
  112. Dubin WR, Waxman HM, Weiss KJ, Amchandani D, Ravani-Petroni C (1985) Rapid tranquillization: the efficacy of oral concentrate. Clin Psychiatry 46: 475–478Google Scholar
  113. Dubin WR, Weiss KJ, Waxman HM (1986) Rapid tranquillization: a comparisation of thiothixen and lozapine. J Clin Psychiatry 46: 475–478Google Scholar
  114. Escobar JI, Barron A, Kiriakos R (1983) A control led study of neuroleptization with fluphenazi- ne hydrochloride injections. J Clin Psycho- pharmacol 3: 359–362Google Scholar
  115. Gelenberg AJ (1983) Rapid neuroleptization. Biol Ther Psychiatry 6: 41Google Scholar
  116. Lerner Y, Lwow E, Levitin A et al. (1979) Acute high-dose parenteral haloperidol treatment in psychosis. Am J Psychiatry 136: 1061–1064PubMedGoogle Scholar
  117. Mirin SM, Weiss RD (1984) Drug use and abuse. In: Bassuk EL, Birk AW (eds) Emergency psychiatry. Concepts, methods and practices. Plenum Press, New York London, pp 141–175Google Scholar
  118. Modell JG, Robert RH, Weiner S (1985) Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol 5: 109–113PubMedGoogle Scholar
  119. Moller HJ, Kissling MD, Lang C, Doerr P, Pirke KM, Von Zerssen D (1982) Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 139: 1571–1575PubMedGoogle Scholar
  120. Neborsky R, Janowsky D, Munson E (1981) Rapid treatment of acute psychotic symptoms with high and low dose haloperidol. Arch Gen Psychiatry 38: 195–199PubMedGoogle Scholar
  121. Nedopil N, Eben E, Klein H, Krüger R, Ruther E, Schmauss M (1985) High-dosage neuroleptic therapy for acute schizophrenic patients–two double-blind studies with benperidol. Pharmacopsychiatry 18: 63–66PubMedGoogle Scholar
  122. Oldham AJ, Bott M (1971) The management of excitement in a general hospital psychiatric ward by high dosage haloperidol. Acta Psychiatr Scand 47: 640–643Google Scholar
  123. Polak P, Laycob L (1971) Rapid tranquillization. Am J Psychiatry 128: 640–643PubMedGoogle Scholar
  124. Reschke RW (1974) Parenteral haloperidol for rapid control of severe disruptive symptoms of acute schizophrenia. Dis Nerv Syst 35: 112115Google Scholar
  125. Resnik M, Burton BT (1984) Droperidol vs haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 45: 298299Google Scholar
  126. Sangiovanni F, Taylor MA, Abrams R, Gaztanaga P (1973) Rapid control of psychotic excitement states with intramuscular haloperidol. Am J Psychiatry 130: 1155–1156PubMedGoogle Scholar
  127. Stotsky BA (1977) Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Dis Nerv Syst 38: 967–973PubMedGoogle Scholar
  128. Tesar GE, Murray GB, Cassem NH (1985) Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. J Clin Psychopharmacol 5: 344–347PubMedGoogle Scholar
  129. Tupin JP (1985) Focal neuroleptization. An approach to optimal dosing for initial and continuing therapy. J Clin Psychopharmacol 5: 1521–1523Google Scholar
  130. Van Leeuwen Amh, Molders J, Sterkmans P, Mie-Lants P, Martens C, Toussaint C, Hovent AM, Desseilles MF, Koch H, Devroye A, Parent M (1977) Droperidol in acutely agitated patients. J Nery Ment Dis 164: 280–283Google Scholar
  131. Walker JI (1980) Psychiatric emergencies. Intervention and resolution. Lippincott, Philadelphia London Mexico City New York St. Louis Sao Paulo Sydney, pp 39–68Google Scholar
  132. Abrams R, Taylor MA (1976) Catatonia, a prospective clinical study. Arch Gen Psychiatry 33: 579–581PubMedGoogle Scholar
  133. Addonizio G, Susman VL, Rom SD (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22: 1004–1020PubMedGoogle Scholar
  134. Allan RN, White HC (1972) Side effects of parenteral longacting phenothiazines. Br Med J 1: 221PubMedGoogle Scholar
  135. Arana GW, Ornsteen ML, Kanter F, Friedman HL, Greenblatt DJ, Shader RI (1986) The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 22: 77–87PubMedGoogle Scholar
  136. Beckmann H, Haas S (1984) Therapie mit Benzodiazepinen: eine Bilanz. Nervenarzt 55: 111–121PubMedGoogle Scholar
  137. Davis JM, Sakkas P, Hua J (1990) Remarks on neuroleptic malignant syndrome after a review of the first 500 cases. In: Steeanis CN et al. (eds) Psychiatry: a world perspective, vol 3. Elsevier Science Publishers B.V. ( Biomedical Division ), pp 262–267Google Scholar
  138. Delay J, Deniker P (1968) Drug-induced extrapyramidal syndroms. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology. Diseases of the basal ganglia, vol 10. North-Holland, Amsterdam, pp 248–266Google Scholar
  139. DE Maio D, Laviani M (1991) Lithium-TCA induced malignant syndrome case report. Prog Neuro Psychopharmacol Biol Psychiatry 15: 427–431Google Scholar
  140. Fricchione GL, Cassem NH, Hooberman D, Hobson D (1983) Intravenous lorazepam in neuroleptic-induced catatonia. J Clin Psychopharmacol 3: 338–342PubMedGoogle Scholar
  141. Gelenberg AJ, Mandel MR (1977) Catatonic reactions to highpotency neuroleptic drugs. Arch Gen Psychiatry 34: 947–950PubMedGoogle Scholar
  142. Geller B, Greydanus DE (1979) Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: two case reports with a literature review. J Clin Psychiatry 40: 102–103PubMedGoogle Scholar
  143. Greenfeld D, Conrad C, Kincare P, Bowers M (1987) Treatment of catatonia with low-dose lorazepam. Am J Psychiatry 144: 1224–1225PubMedGoogle Scholar
  144. Grunhaus L, Sancovici S, Rimon R (1979) Neuroleptic malignant syndrome due to depot fluphenazine. J Clin Psychiatry 40: 99–100PubMedGoogle Scholar
  145. Haefely W (1983) The biological basis of benzodiazepine actions. J Psychoact Drugs 15: 19–39Google Scholar
  146. Häfner H, Kasper S (1982) Akute lebensbedrohliche Katatonie. Nervenarzt 53: 385–394PubMedGoogle Scholar
  147. Halman M, Goldbloom DS (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28: 518–521PubMedGoogle Scholar
  148. Hermesh H, Aizenberg D, Weizman A, Lapidot M, Mayor C, Munitz H (1992) Risk for definite neuroleptic malignant syndrome. Br J Psychiatry 161: 254–257Google Scholar
  149. Heuser I, Benkert O (1986) Lorazepam for short-term alleviation of stupor and mutism. J Clin Psychopharmacol 62: 62Google Scholar
  150. Hippius H, Ruther E, Schmauss M (1989) Katatone and dyskinetische Syndrome. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  151. Kahlbaum KL (1874) Die Katatonie. Hirschwald, BerlinGoogle Scholar
  152. Kaufmann CA, Wyatt RJ (1987) Neuroleptic malignant syndrome. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1421–1430Google Scholar
  153. Kellam AM (1987) The neuroleptic malignant syndrome, socalled. A survey of the world literature. Br J Psychiatry 150: 752–759PubMedGoogle Scholar
  154. Kick H (1981) Die katatone Hyperthermie. Nervenarzt 52: 51–55PubMedGoogle Scholar
  155. Lew TY, Tollefson G (1983) Chlorpromazin-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 18: 1441–1446PubMedGoogle Scholar
  156. Mcevoy JP, Lohr JB (1984) Diazepam for catatonia. Am J Psychiatry 141: 284–285PubMedGoogle Scholar
  157. Meltzer HY (1973) Hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia 29: 337–346PubMedGoogle Scholar
  158. Modestin J, Toffler G, Pia M, Greub E (1983) Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens. Pharmacopsychiatry 16: 121–126Google Scholar
  159. Moller HJ, Kissling W, Lang C, Doerr P, Prike KM, V Zerrsen D (1982) Efficacy and side effects of haloperidol in psychiatric patients: oral vs. intravenous administration. Am J Psychiatry 139: 1571–1575PubMedGoogle Scholar
  160. Morrison JR (1973) Catatonia. Retarded and exci- ted types. Arch Gen Psychiatry 28: 39–41PubMedGoogle Scholar
  161. Müller T, Becker T, Fritze J (1988) Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet ii: 1500Google Scholar
  162. Neborsky R, Janowsky D, Munson E, Deprey D (1981) Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Arch Gen Psychiatry 38: 195–199PubMedGoogle Scholar
  163. Pennati A, Sacchetti E, Calzeroni A (1991) Dantrolene in lethal catatonia. Am J Psychiatry 148 (2): 268PubMedGoogle Scholar
  164. Regestein QR, Alpert JS, Reich P (1977) Sudden catatonic stupor with disastrous outcome. JAMA 238: 618–620PubMedGoogle Scholar
  165. Rosebush P, Mazurek MF (1991) Serum iron and neuroleptic malignant syndrome. Lancet 338: 149–151PubMedGoogle Scholar
  166. Rosebush P, Stewart T, Mazurek MF (1991) The treatment of neuroleptic malignant syndome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 159: 709–712PubMedGoogle Scholar
  167. Ruhland M, Fuchs AM (1986) Lack of antagonism by Ro 15–1788 on timelotem (KC 7507) — a benzodiazepine with antipsychotic and anxiolytic properties. Pharmacopsychiatry 19: 216–217Google Scholar
  168. Ruhland M, Tuolp M, Muesch HR, Fuchs AM (1986) Timelotem an antipsychotic benzodiazepine derivative. Pharmacopsychiatry 19: 218–219Google Scholar
  169. Sakkas P, Davis JM, Janicak PG, Wang Z (1991) Drug treatment of the neuroleptic malignant syndrome. Psychopharmacology 27: 381–385Google Scholar
  170. Salam SA, Pillai AK, Bereford TP (1987) Lorazepam for psychogenic catatonia. Am J Psychiatry 144: 1082–1083PubMedGoogle Scholar
  171. Sauer H, Lauter H (1987) Elektrokrampftherapie. I. Wirksamkeit und Nebenwirkungen der Elektrokrampftherapie. Nervenarzt 58: 201–209Google Scholar
  172. Sauer H, Lauter H (1987) Elektrokrampftherapie. II. Indikationen und Kontraindikationen und therapeutische Technik der Elektrokrampftherapie. Nervenarzt 58: 211–218Google Scholar
  173. Scott J (1984) Dantrolene for neuroleptic ma- lignant syndrome. Br J Psychiatry 43: 98Google Scholar
  174. Settle EC, Ayd FJ (1983) Haloperidol: a quarter century of experience. J Clin Psychiatry 44: 440–448PubMedGoogle Scholar
  175. Shalev A, Munitz H (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 73: 337–347PubMedGoogle Scholar
  176. Spiess-Kiefer C, Hippius H (1986) Malignes neuroleptisches Syndrom und maligne Hyperthermie — ein Vergleich. Fortschr Neurol Psychiat 54: 158–170PubMedGoogle Scholar
  177. Walter-Ryan WG (1985) Treatment for catatonic symptoms with intramuscular lorazepam. J Clin Psychopharmacol 5: 123–124Google Scholar
  178. Ward A, Chaffman O, Sorkin M (1986) Dantrolene, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drug 32: 130–168Google Scholar
  179. Weinberger DR, Kelly MJ (1977) Catatonia and malignant syndrome: a possible complication of neuroleptic administration. J Nerv Ment Dis 165: 263–268PubMedGoogle Scholar
  180. Wetzel H, Heuser I, Benkert O (1988) Benzodiazepines for catatonic symptoms, stupor, and mutism. Pharmacopsychiatry 21: 394–395PubMedGoogle Scholar
  181. Bittkali S, Kuhn W, Bogdahn U, Przuntek H (1989) Akinetische Krise bei Morbus Parkinson — Er- fahrungen mit Lisurid (i.v.). In: Bogdahn U, Mertens HG (Hrsg) Prognostik in der Inten- sivtherapie des Zentralnervensystems. Sprin- ger, Berlin Heidelberg New York Tokyo, S 263–270Google Scholar
  182. Cordt A, Schlegel U, Jerusalem F (1986) Malignes Dopa-Entzugs-Syndrom ( MDES ). Akt Neurol 13: 99–101Google Scholar
  183. Klewin IR, Bittkau S, Suchy I, Przuntek H (1989) Kontinuierliche dopaminerge Stimulation durch subkutane Lisuridapplikation — Erfahrungen mit 28 Patienten. In: Bogdahn U, Mer-Tens HG (Hrsg) Prognostik in der Intensivtherapie des Zentralnervensystems. Springer, Berlin Heidelberg New York Tokyo, S 257–262Google Scholar
  184. Przuntek H (1989) Intensivmedizinische Probleme bei der Therapie extrapyramidalmotorischer Erkrankungen. In: Bogdahn U, Mertens HG (Hrsg) Prognostik in der Intensivtherapie des Zentralnervensystems. Springer, Berlin Heidelberg New York Tokyo, S 249–256Google Scholar

Copyright information

© Springer-Verlag Wien 1992

Authors and Affiliations

  • H. Berzewski
  • G. Laux
  • L. Frölich
  • J. Fritze
  • H. Przuntek

There are no affiliations available

Personalised recommendations